Browse Health
Primary Care Doctor, Family Practitioner
33 years of experience
Accepting new patients


Education ?

Medical School Score
A.T. Still University - Kirksville (1979) *
Phoenix General Hospital (1980) *
Family Medicine
* This information was reported to Vitals by the doctor or doctor's office.

Awards & Distinctions ?

Patients' Choice 5th Anniversary Award (2012 - 2014)
Patients' Choice Award (2008 - 2014)
Compassionate Doctor Award - 5 Year Honoree (2013 - 2014)
Compassionate Doctor Recognition (2009 - 2014)
Top 10 Doctor - Neighborhood (2014)
Downtown Scottsdale
Family Practitioner
Top 10 Doctor - State (2014)
Family Practitioner
Top 10 Doctor - Metro Area (2014)
Phoenix Metro Area
Family Practitioner
Top 10 Doctor - City (2014)
Scottsdale, AZ
Family Practitioner
On-Time Doctor Award (2009, 2014)
Midwestern University College of Osteopathic Medicine
Adjunct Professor - Family Medicine

Affiliations ?

Dr. Lillo is affiliated with 2 hospitals.

Hospital Affiliations



  • Scottsdale Healthcare-Shea
    9003 E Shea Blvd, Scottsdale, AZ 85260
    Top 25%
  • Scottsdale Healthcare-Osborn
    7400 E Osborn Rd, Scottsdale, AZ 85251
    Top 50%
  • Publications & Research

    Dr. Lillo has contributed to 4 publications.
    Title Obesity As a Disease State: a New Paradigm for Diagnosis and Treatment.
    Date December 2009
    Journal Clinical Cornerstone

    While global prevalence of obesity continues to increase dramatically, treatment options remain less than optimal. The etiology of obesity is multifactorial, ranging from lifestyle choices such as excess food intake and insufficient physical activity, to use of medications that have weight gain as an undesirable side effect. Economic and political determinants of available foodstuffs and even social networks may also contribute to obesity. Successful management of obesity requires the understanding and acceptance of a new paradigm that identifies obesity as a disease--one defined by waist circumference--that requires treatment. Obesity meets all accepted criteria of a medical disease, including a known etiology, recognized signs and symptoms, and a range of structural and functional changes that culminate in pathologic consequences. Excess adipose tissue acts as an endocrine organ to produce excess free fatty acids, as well as tumor necrosis factor-alpha, interleukin-6, leptin, and plasminogen activator inhibitor-1. These bioactive molecules are associated with hyperinsulinemia, hyperglycemia, insulin resistance, development of diabetes, endothelial damage, and the onset and progression of atherosclerotic lesions. Options for treating obesity include lifestyle modifications (dietary changes, increased physical activity, behavior modification) and, for the morbidly obese, surgery. Lifestyle modification is rarely successful over the long term; therefore, addition of pharmacotherapy should be considered for obese individuals who have difficulty achieving and maintaining weight goals with lifestyle modifications alone. Several weight loss drugs are available for long-term use, with others in various stages of clinical development.

    Title The Endocannabinoid System As a Novel Approach for Managing Obesity.
    Date October 2007
    Journal The Journal of the American Osteopathic Association

    The recent discovery of the endocannabinoid system has led to the development of promising treatments for patients with obesity and associated cardiometabolic risk factors. Basic research has demonstrated that the endocannabinoid system plays an integral role in the regulation of food intake, metabolism, and storage. Research with the endocannabinoid receptor antagonist rimonabant has demonstrated statistically significant improvements in body weight, fasting insulin levels, glucose tolerance, high-density lipoprotein cholesterol levels, serum triglyceride levels, and waist circumference, compared with placebo. Rimonabant has also produced statistically significant improvements in inflammatory markers. Research with rimonabant has demonstrated sustained efficacy for as long as 2 years when used in conjunction with a reduced-calorie diet and moderate physical activity. Rimonabant is the first cannabinoid receptor 1 antagonist to be marketed in Europe and the first to file an New Drug Application in the United States. It may provide a novel therapeutic strategy for the treatment of patients with obesity and associated cardiometabolic risk factors.

    Title Cardiometabolic Risk Modification: Current Trends and Emerging Therapies.
    Date March 2007
    Journal Jaapa : Official Journal of the American Academy of Physician Assistants
    Title [clinical Trial with Oxytryptan in Depressions]
    Date February 1982
    Journal Actas Luso-españolas De Neurología, Psiquiatría Y Ciencias Afines

    Similar doctors nearby

    Dr. Rahul Athalye

    Family Medicine
    9 years experience
    Scottsdale, AZ

    Dr. Frederick Dicke

    Family Medicine
    26 years experience
    Scottsdale, AZ

    Dr. Edward Oleary

    Family Medicine
    10 years experience
    Scottsdale, AZ

    Dr. Jennifer King

    Family Medicine
    11 years experience
    Scottsdale, AZ

    Dr. Richard Kiraly

    General Practice
    Scottsdale, AZ

    Dr. Andrea Darby Stewart

    Family Medicine
    15 years experience
    Scottsdale, AZ
    Search All Similar Doctors